Table 1 Clinicopathological characteristics of patients with pancreatic cancer, stratified according to GNRI and PMV
Characteristics | GNRI | P | PMV | P | ||
|---|---|---|---|---|---|---|
>  98 (n = 55) | ≤ 98 (n = 50) | High group (n = 60) | Low group (n = 45) | |||
Age, years, median (range) | 73.4 (65–84) | 75.4 (66–85) | 0.057 | 73.3 (65–85) | 76.2 (67–85) | 0.013 |
Sex (male, %) | 26 (56.2%) | 33 (66.0%) | 0.053 | 29 (48.3%) | 30 (66.7%) | 0.061 |
Body mass index, kg/m2, median (range) | 22.8 (17.4–30.0) | 20.5 (14.0–29.4) | <  0.001 | 22.8 (17.7–30.0) | 20.4 (14.0–28.5) | <  0.001 |
Tumor size, mm, median (range) | 25.6 (10.0–60.0) | 27.5 (4.0–60.0) | 0.338 | 25.7 (13.0–60) | 27.6 (4.0–60.0) | 0.766 |
Tumor location (head, %) | 25 (45.5%) | 32 (64.0) | 0.057 | 33 (55.0%) | 24 (53.3%) | 0.865 |
Histological grading (G1, %) | 30 (54.5%) | 27 (54.0%) | 0.955 | 35 (58.3%) | 22 (48.9%) | 0.336 |
Resectability status (BR-PC, %) | 2 (3.6%) | 0 (0.0%) | 0.496 | 1 (1.7%) | 1 (2.2%) | 1.000 |
Lymph node metastasis (present, %) | 26 (47.3%) | 32 (64.0%) | 0.085 | 34 (56.7%) | 24 (53.3%) | 0.734 |
ASA-PS (1 or 2, %) | 47 (85.5%) | 35 (70%) | 0.056 | 51 (85.0%) | 31 (68.9%) | 0.048 |
Preoperative albumin, g/dL, median (range) | 4.2 (3.8–4.9) | 3.7 (2.1–4.3) | <  0.001 | 4.0 (2.8–4.9) | 3.9 (2.1–4.7) | 0.033 |
Preoperative lymphocyte count, median (range) | 1495 (140–3800) | 1560 (400–6660) | 0.947 | 1512 (140–6660) | 1536 (400–3016) | 0.763 |
Preoperative CA19–9, U/mL, median (range) | 59.0 (0.7–3221.0) | 63.7 (0.7–3270.7) | 0.599 | 59.1 (0.7–3221) | 60.8 (0.7–3270.7) | 0.591 |
Neoadjuvant chemotherapy (present, %) | 8 (14.5%) | 4 (8.0%) | 0.366 | 6 (10.0%) | 6 (13.3%) | 0.595 |
Adjuvant chemotherapy (present, %) | 32 (60.4%) | 27 (55.1%) | 0.590 | 39 (67.2%) | 20 (45.5%) | 0.027 |